Pierre Balard | Research Lead, Vaccine Product Development
Wellcome Trust

Pre-Congress Workshops - Monday 30th March @ 10:00

ANTIMICROBIAL RESISTANCE WORKSHOP

Workshop Chair: Dr Christian Harding, CSO and Co-Founder, Omniose

• 10.00 Chair’s Opening Remarks
• 10:10 Keynote Intro – Impact of Vaccines on AMR 
• 10.30 Advancing Immunity: Clinical Development of a Peptide Conjugate Vaccine for Group A Streptococcus
• 10.45 Leveraging Serological Insights to Combat Emerging Pathogens and Antimicrobial Resistance
• 11.00 The Cost of Inaction: Quantifying the Economic Value of Vaccines in the Fight Against AMR
• 11.15 Two Targets, One Construct: Psl-PcrV Bioconjugate Vaccine to Tame P. aeruginosa
• 11.30 AMR, Biodefence and National Security: They’re All Connected
• 12:00 Mitigating AMR in LMICs: The Role of Vaccines in a One Health World
• 12.15 Panel Discussion: Perceptions of AMR Vaccine Development in the Current Global Climate
• 14:00 – 15:00 Funding Pipeline Updates
  • 14:00 Gates Foundation
  • 14:20 Wellcome Trust
  • 14:40 Adjuvant Capital
  • 15:00- 16:00 AMR Vaccines Development Updates
    • 15:00 Applying HIV vaccine design principles to Shigella & Acinetobacter
    • 15:15 Universal Pneumococcal Vaccine Development 
    • 15:30 From Immunity to Impact: Building Executable Vaccines Against Klebsiella pneumoniae
    • 15:45 Advancing a multivalent vaccine candidate to prevent S.aureus skin infections
• 16:00 Panel: Are Combination Vaccines the Way Forward for AMR /Defining the Value of Combo Vaccines?
  • Economic valuation of vaccines with reduction on AMR
  • Improving coverage of viral vaccines which reduce AMR
  • Explore the concept of Syndromic vaccines

Christian Harding, CSO & Co-founder, Omniose

Michael Good, Head, Laboratory of Vaccines for the Developing World, and NHMRC Investigator Fellow, Institute For Glycomics

×

Michael Good / ANTIMICROBIAL RESISTANCE WORKSHOP

Michael Good, Head, Laboratory of Vaccines for the Developing World, and NHMRC Investigator Fellow,
Institute For Glycomics

Professor Michael Good is a Principal Research Leader at the Institute for Biomedicine and Glycomics, Griffith University, Australia.  He heads the Laboratory of Vaccines for the Developing World.  He has developed candidate vaccines for the prevention of malaria and streptococcus and these have...

CloseMore

Valeria Szijarto, Director of Bacterial Vaccine Discovery, AstraZeneca

Usman Nakakana, Senior Program Officer Clinical Vaccine Development and Impact, Gates Foundation

Jon Heinrichs, VP, IAVI

×

Jon Heinrichs / ANTIMICROBIAL RESISTANCE WORKSHOP

Jon Heinrichs, VP,
IAVI

Jon Heinrichs is Vice President and head of Discovery Science at IAVI, based in New York City. His responsibilities include advancing broadly neutralizing antibodies for HIV prevention and leading IAVI’s three laboratories, based in La Jolla, CA, Jersey City, NJ, and New Delhi, India. Prior to...

CloseMore

Bill Hausdorff, Lead, Meningococcal Vaccine Development and Vaccines Public Health Value Proposition and, PATH, Center for Vaccine Innovation and Access

×

Bill Hausdorff / ANTIMICROBIAL RESISTANCE WORKSHOP

Bill Hausdorff, Lead, Meningococcal Vaccine Development and Vaccines Public Health Value Proposition and,
PATH, Center for Vaccine Innovation and Access

Trained as a biochemist at the Johns Hopkins University, the US National Institutes of Health and Duke University, Bill Hausdorff’s vaccine career started at the US Agency for International Development and Centers for Disease Control in Washington DC and Cairo, Egypt, where he worked to catalyze...

CloseMore

James Wassil, COO, Vaxcyte

×

James Wassil / ANTIMICROBIAL RESISTANCE WORKSHOP

James Wassil, COO,
Vaxcyte

Jim brings over three decades of experience developing and commercializing vaccines intended to treat or prevent diseases that impact children and adults around the world. During this time, he held significant leadership positions in the vaccine divisions of Pfizer, Novartis and Merck. Prior to...

CloseMore

Session led by:

×

Tim Hirst / ANTIMICROBIAL RESISTANCE WORKSHOP

Tim Hirst, CEO,
GPN Vaccines Ltd

Tim is the Chairman & CEO of GPN Vaccines. He has extensive expertise in the life sciences, executive management and venture capital investment. Tim was previously CEO of ANU Connect Ventures, a $30M pre-seed VC fund, the Deputy Vice Chancellor for Research & Innovation at The University of ...

CloseMore

Holy Akwar, Science Advisor, Veterinary & AMR, International Centre for Antimicrobial Resistance Solutions (ICARS)

×

Holy Akwar / ANTIMICROBIAL RESISTANCE WORKSHOP

Holy Akwar, Science Advisor, Veterinary & AMR,
International Centre for Antimicrobial Resistance Solutions (ICARS)

  Dr. Akwar is the Science Advisor for Veterinary Sciences and AMR at the International Centre for Antimicrobial Resistance Solutions (ICARS). He leads the development and implementation of technical initiatives designed to generate evidence on AMR mitigation and enhance preventive health...

CloseMore

Session led by:

×

Juan Jose Indante / ANTIMICROBIAL RESISTANCE WORKSHOP

Juan Jose Indante, Chief Executive Officer,
Vaxdyn

Juanjo is a biochemist, microbiologist, and business developer in biotechnology. He’s the CEO and principal investigator in Vaxdyn, a vaccine developer headquartered in Spain. With support from CARB-X, the European Commission, and private investors, Vaxdyn has developed a unique vaccine technology...

CloseMore

Galit Alter, VP, Early Development for Vaccines & Immune Therapies, AstraZeneca

Pierre Balard, Research Lead, Vaccine Product Development, Wellcome Trust

×

Pierre Balard / ANTIMICROBIAL RESISTANCE WORKSHOP

Pierre Balard, Research Lead, Vaccine Product Development,
Wellcome Trust

Pierre is a pharmacist trained in France (Pharm.D.) with 10+ years of experience all along the healthcare spectrum: Big Pharma (market access & pricing), Biotech consulting, R&D Research Labs/academia, Retail Pharmacy, Hospitals, and Global Health philanthropy. Since joining the Wellcome...

CloseMore

Michael Kowarik, CSO, LimmaTech Biologics AG

Jonathan Daniels, US Policy Director, AMR Action Fund

David Humphreys, Executive Advisor, Triangulate Health Ltd

Rino Rappuoli, Scientific Director, Fondazione Biotecnopolo di Siena

×

Rino Rappuoli / ANTIMICROBIAL RESISTANCE WORKSHOP

Rino Rappuoli, Scientific Director,
Fondazione Biotecnopolo di Siena

Rino Rappuoli is Scientific Director of the Biotecnopolo di Siena Foundation, Italy.  He is also Honorary Professor of Vaccinology at Imperial College, London, and Senior Professor of Molecular Biology at the University of Siena. Prior positions held: Head R&D and Chief Scientist at GSK...

CloseMore

Jomana Musmar, CEO, AMR Strategic Coalitions & AGH

×

Jomana Musmar / ANTIMICROBIAL RESISTANCE WORKSHOP

Jomana Musmar, CEO,
AMR Strategic Coalitions & AGH

Dr. Jomana Musmar is a distinguished global policy expert and result-oriented leader with decades of intimate government experience within the U.S. Departments of Health and Human Services (HHS), Defense (DoD), and Agriculture (USDA). She excels in cross-functional coordination, strategic...

CloseMore

Paul Friedrichs, Senior Adviser, CSIS Global Health Policy Center

Giulia Balconi, Investor, ADJUVANT CAPITAL

×

Giulia Balconi / ANTIMICROBIAL RESISTANCE WORKSHOP

Giulia Balconi, Investor,
ADJUVANT CAPITAL

Giulia is an investor at Adjuvant Capital, a life science venture capital firm investing in promising technologies for high-burden public health challenges. Giulia has a background in business, finance, and public health. She started her career as an investment banker at J.P. Morgan in London...

CloseMore

Khatuna Giorgadze, Partner, Linksbridge SPC

×

Khatuna Giorgadze / ANTIMICROBIAL RESISTANCE WORKSHOP

Khatuna Giorgadze, Partner,
Linksbridge SPC

Khatuna Giorgadze brings over 20 years of experience in global health, life sciences and international development to her role as a partner in Linksbridge’s Seattle office. She’s led market dynamics engagements for the past dozen years, focusing on improving market access and enabling data-driven...

CloseMore